# US 2011/0257095 A1 · Pharmaceutical compositions and related methods of delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257095 A1
- Document ID: US20110257095A1
- Status: Published application
- Kind: A1
- Application number: 12/981,036
- Filed: 2010-12-29
- Published: 2011-10-20
- Earliest claimed: 2008-09-17
- Inventors: Paul Salama; Roni Mamluk; Karen Marom; Irina Karmeli; Yaron Ilan; Moshe Tzabari
- Web page: https://patentgrep.com/patent/US20110257095A1

## CPC

- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 31/721: Dextrans
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 38/212: {IFN-alpha}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/26: Glucagons
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/02: of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/1021: {against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons}
- A61K 51/1024: {against hormones, hormone-releasing or hormone-inhibiting factors}
- A61K 51/1045: {against animal or human tumor cells or tumor cell determinants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

## Claims

### Claim at position 1

1-195. (canceled)

### Claim 196

A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.

### Claim 197 (depends on 196)

The method of claim 196, wherein the somatostatin analog is octeotride.

### Claim 198 (depends on 196)

The method of claim 196, wherein the prophylaxis is primary.

### Claim 199 (depends on 196)

The method of claim 196, wherein the prophylaxis is secondary.

### Claim 200 (depends on 196)

The method of claim 196, wherein the variceal bleeding is associated with portal hypertension.

### Claim 201 (depends on 196)

The method of claim 196, wherein the varices are gastric or esophageal.

### Claim 202 (depends on 196)

The method of claim 196, wherein the somatostatin analog is administered once daily.

### Claim 203 (depends on 196)

The method of claim 196, wherein the somatostatin analog is administered twice or more daily.

### Claim 204

A method of treating a subject suffering from portal hypertension or variceal bleeding, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.

### Claim 205 (depends on 204)

The method of claim 204, wherein the somatostatin analog is octeotride.

### Claim 206 (depends on 204)

The method of claim 204, wherein the subject suffers from variceal bleeding.

### Claim 207 (depends on 204)

The method of claim 204, wherein the varices are gastric or esophageal.

### Claim 208 (depends on 204)

The method of claim 204, wherein the subject suffers from portal hypertension.

### Claim 209 (depends on 204)

The method of claim 204, wherein the therapeutic agent is administered once daily.

### Claim 210 (depends on 204)

The method of claim 204, wherein the therapeutic agent is administered twice or more daily.

### Claim 211

A method of treating a subject suffering from abnormal GI motility, flushing episodes associated with carcinoid syndrome, an endocrine tumor (such as carcinoids, VIPoma), gastroparesis, diarrhea, pancreatic leak or a pancreatic pseudo-cyst, or hepato-renal syndrome, shock of hypovolemic (e.g. hemorrhagic) or vasodilatory (e.g. septic) origin, cardiopulmonary resuscitation or anesthesia-induced hypotension, comprising orally administering to the subject a somatostatin analog or a composition comprising a somatostatin analog.

### Claim 212 (depends on 211)

The method of claim 211, wherein the somatostatin analog is octeotride.

### Claim 213

A method of prophylactically treating a subject for variceal bleeding, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog.

### Claim 214 (depends on 213)

The method of claim 213, wherein the vasopressin analog is terlipressin.

### Claim 215 (depends on 213)

The method of claim 213, wherein the prophylaxis is primary.

### Claim 216 (depends on 213)

The method of claim 213, wherein the prophylaxis is secondary.

### Claim 217 (depends on 213)

The method of claim 213, wherein the variceal bleeding is associated with portal hypertension.

### Claim 218 (depends on 213)

The method of claim 213, wherein the therapeutic agent is administered once daily.

### Claim 219 (depends on 213)

The method of claim 213, wherein the therapeutic agent is administered twice or more daily.

### Claim 220

A method of treating a subject suffering from hepato-renal syndrome (HRS), bleeding esophageal varices or portal hypertension, which comprises orally administering to the subject a vasopressin analog or a composition comprising a vasopressin analog.

### Claim 221 (depends on 220)

The method of claim 220, wherein the subject suffers from hepato-renal syndrome (HRS).

### Claim 222 (depends on 220)

The method of claim 220, wherein the hepato-renal syndrome (HRS) is HRS I.

### Claim 223 (depends on 220)

The method of claim 220, wherein the hepato-renal syndrome (HRS) is HRS II.

### Claim 224 (depends on 220)

The method of claim 220, wherein the subject suffers from bleeding esophageal varices.

### Claim 225 (depends on 220)

The method of claim 220, wherein the subject suffers from portal hypertension.

### Claim 226 (depends on 220)

The method of claim 220, wherein the vasopres sin analog is terlipressin.

### Claim 227 (depends on 220)

The method of claim 220, wherein the variceal bleeding is associated with portal hypertension.

### Claim 228 (depends on 220)

The method of claim 220, wherein the varices are gastric or esophageal.

### Claim 229 (depends on 220)

The method of claim 220, wherein the therapeutic agent is administered once daily.

### Claim 230 (depends on 220)

The method of claim 220, wherein the therapeutic agent is administered twice or more daily.
